Annual General Meeting Elects New Supervisory Board

We hold our 29th Annual General Meeting in virtual form today. All resolutions on the agenda were approved.

26 Apr 2024 | Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, held its 29th Annual General Meeting in virtual form today. All resolutions on the agenda, including the proposed dividend of € 2.20 per share, were approved by a large majority. In addition, the Annual General Meeting elected six new shareholder representatives to the Supervisory Board.

In her address to the shareholders, Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany, summarized the developments of the previous fiscal year and provided an outlook for the future: “2023 was a transition year in which we proved our resilience, keeping our dividend at the same level as 2022, illustrating our confidence in the future. In 2024, we will gradually return to growth. Moreover, we are well positioned to achieve long-term growth, driven by strong megatrends in all our key markets.”

In the Supervisory Board elections, which took place this year as scheduled, the Annual General Meeting elected the new members, including four women. Specifically, the following members will represent the shareholders in the new Supervisory Board: Michael Kleinemeier (Chair), Katja Garcia Vila, Dr. Carla Kriwet, Barbara Lambert, Prof. Dr. Stefan Palzer, and Dr. Susanne Schaffert. The new representatives of the Merck family appointed to the Supervisory Board by E. Merck Beteiligungen KG are Dr. Daniel Thelen and Professor Simon Thelen. In the future, employees will be represented in the Supervisory Board by Sascha Held (Vice Chair), Birgit Biermann, Anne Lange, Dietmar Oeter, Alexander Putz, Christian Raabe, Michael Reinhart, and Sandra Schwebke. In its constitutive meeting after the Annual General Meeting, the Supervisory Board elected Michael Kleinemeier as Chair. He has been a member of the Supervisory Board since 2019 and has served as Chair since early 2024.

“I am grateful to have been elected as Chair of the Supervisory Board and am looking forward to the task of accompanying the company on its further growth path,” said Michael Kleinemeier after his election today. “I would also like to thank the Supervisory Board members retiring today for the trustful and positive collaboration within this important Board. In addition, I am looking forward to an equally constructive collaboration with all remaining members as well as those who were newly elected today.”

When the resolutions were voted on, around 92.7 million of the approximately 129.2 million shares issued were represented, corresponding to 71.78 % of the share capital. A detailed summary of the voting results as well as additional information can be found at www.emdgroup.com/agm.

Downloads

For more information, contact Gangolf Schrimpf

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Related News

  1. Press Releases

    Off to a Good Start in Fiscal 2024

    The positive development of Healthcare and Electronics largely compensated for the decline in Life Science.

    2024/05/15